Rankings
▼
Calendar
XLO
Xilio Therapeutics, Inc.
$28M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
Gross Profit
$2M
100.0% margin
Operating Income
-$15M
-652.3% margin
Net Income
-$14M
-619.5% margin
EPS (Diluted)
$-0.22
QoQ Revenue Growth
-4.0%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$14M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$75M
Total Liabilities
$54M
Stockholders' Equity
$21M
Cash & Equivalents
$61M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$0
—
Gross Profit
$2M
$0
—
Operating Income
-$15M
-$17M
+15.0%
Net Income
-$14M
-$17M
+16.3%
← FY 2024
All Quarters
Q4 2024 →
XLO Q3 2024 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena